Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of CDI-31244 in Healthy and HCV Subjects
NCT02760758Phase 1Completed
- Sponsor
- Cocrystal Pharma
- Start
- Apr 2016
- Primary completion
- Mar 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of CDI-31244 in hepatitis C (HCV) (11 cohorts), sponsored by Cocrystal Pharma. Primary endpoint: Number of treatment emergent adverse events. Started Apr 2016; status: completed.
02
Drugs
CDI-31244
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT02760758.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02760758.